Download PDF
Drug Res (Stuttg) 2017; 67(07): 377-384
DOI: 10.1055/s-0043-109788
Review
© Georg Thieme Verlag KG Stuttgart · New York

Paediatric Medicines: Regulatory and Scientific Issues

Chrysa Daousani
1   Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece
,
Vangelis D. Karalis
1   Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece
› Author Affiliations
Further Information

Publication History

received 20 February 2017

accepted 21 April 2017

Publication Date:
18 May 2017 (online)

Also available at
    Permissions and Reprints

Abstract

In the past, dosage regimens authorized for adults were extrapolated to children relying mainly on empirical dosage adjustments. However, children are not small adults, but a distinct and heterogeneous group in terms of physiology, disease occurrence, pharmacokinetics, pharmacodynamics and also psychological, cognitive, and behavioral aspects. Even though it would be helpful to know the physiological changes and the special drug treatment needs in children, this task could not be performed due to ethical reasons. Important issues to consider for the development of paediatric drug products refer to the administration of the accurate dose, the use of the appropriate excipients, and acceptability. The latter is crucial and taste-screening methods (like electronic tongues) have been developed. A new era in paediatric medicines started with the entry into force of paediatric regulations. In the early ‘80s, the FDA started the set-up of a regulatory framework by authorizing issues like the Paediatric Rule, the Best Pharmaceuticals for Children Act, the Paediatric Research Equity Act, and the Food and Drug Administration Safety and Innovation Act. Similar efforts have been made in the EU, mainly through the entry into force of the Paediatric Regulation and the establishment of the Paediatric Committee, the Paediatric Investigation Plan, the Paediatric Use Marketing Authorization, and the European Paediatric Research Network. Other efforts to bridge the gap, between knowledge in adults and the children’s special requirements, include the extrapolation concept of safety/efficacy aspects, the application of modeling/simulation approaches in paediatric drug development, and the development of a paediatric Biopharmaceutics Classification Scheme.

Key words

Paediatric medicines - Paediatric regulatory framework - Extrapolation concept
 

  • References

  • 1 Ernest TB, Elder DP, Martini LG. et al. Developing paediatric medicines: Identifying the needs and recognizing the challenges. J Pharm Pharmacol 2007; 59: 1043-1055
    CrossrefPubMedGoogle Scholar
  • 2 Ivanovska V, Rademaker CM, van Dijk L. et al. Pediatric drug formulations: A review of challenges and progress. Pediatrics 2014; 134: 361-372
    CrossrefPubMedGoogle Scholar
  • 3 Bartelink I, Rademaker C, Schobben A. et al. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006; 45: 1077-1097
    CrossrefPubMedGoogle Scholar
  • 4 Mason J, Pirmohamed M, Nunn T. Off-label and unlicensed medicine use and adverse drug reactions in children: A narrative review of the literature. Eur J Clin Pharmacol 2012; 68: 21-28
    CrossrefPubMedGoogle Scholar
  • 5 Nahata MC. Lack of pediatric drug formulations. Pediatrics 1999; 104: 607-609
    PubMedGoogle Scholar
  • 6 Nahata MC, Allen LV. Extemporaneous drug formulations. Clin Ther 2008; 30: 2112-2119
    CrossrefPubMedGoogle Scholar
  • 7 Mennella JA, Beauchamp GK. Optimizing oral medications for children. Clin Ther 2008; 30: 2120-2132
    CrossrefPubMedGoogle Scholar
  • 8 Cram A, Breitkreutz J, Desset-Brèthes S. et al. Challenges of developing palatable oral paediatric formulations. Int J Pharm 2009; 365: 1-3
    CrossrefPubMedGoogle Scholar
  • 9 Davies EH, Tuleu C. Medicines for children: A matter of taste. J Pediatr 2008; 153: 599-604
    CrossrefPubMedGoogle Scholar
  • 10 Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv 2007; 4: 37-45
    CrossrefPubMedGoogle Scholar
  • 11 Stegemann S, Gosch M, Breitkreutz J. Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. Int J Pharm 2012; 430: 197-206
    CrossrefPubMedGoogle Scholar
  • 12 Best BM, Capparelli EV, Diep H. et al. Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children. J Acquir Immune Defic Syndr 2011; 58: 385-391
    CrossrefPubMedGoogle Scholar
  • 13 European Medicines Agency. Ethical considerations for paediatric trials. How can ethics committees of the member states and the paediatric committee at the european medicines agency work together? Report on an international meeting at the european medicines agency 30 November – 1 December 2011; 2012.
    PubMed
  • 14 Milne CP, Bruss JB. The economics of pediatric formulation development for off-patent drugs. Clin Ther 2008; 30: 2133-2145
    CrossrefPubMedGoogle Scholar
  • 15 Joseph PD, Craig JC, Caldwell P. Clinical trials in children. Br J Clin Pharmacol 2015; 79: 357-369
    CrossrefPubMedGoogle Scholar
  • 16 International Conference of Harmonisation. ICH Topic E11. Clinical Investigation of medicinal products in the paediatric population. 2001
    PubMed
  • 17 Food and Drug Administration. Center for Drug Evaluation and Research (CDER), guidance for industry: General considerations for the clinical evaluation of drugs in infants and children. 1977
    PubMed
  • 18 European Medicines Agency. Reflection paper: Formulations of choice for the paediatric population. 2006
    PubMed
  • 19 European Medicines Agency. Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population. 2006
    PubMed
  • 20 European Medicines Agency. Guideline on the investigation of medicinal products in term and preterm neonate. 2007
    PubMed
  • 21 European Medicines Agency. Guideline on pharmaceutical development of medicines for paediatric use. 2013
    PubMed
  • 22 European Medicines Agency. Report on the survey of all paediatric uses of medicinal products in Europe. Established according to article 42-43 of Regulation (EC) No 1901/2006 of the European Parliament and of the Council on medicinal products for Paediatric use. 2010
    PubMed
  • 23 National Institute of Health, National Institute of Child Health and Human Development. Best Pharmaceuticals for Children. Status of Drugs Listed by NICHD. 2016
    PubMed
  • 24 Samardzic J, Allegaert K, Bajcetic M. Developmental pharmacology: A moving target. Int J Pharm 2015; 492: 335-337
    CrossrefPubMedGoogle Scholar
  • 25 O'Hara K, Wright IM, Schneider J. et al. Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future. Br J Clin Pharmacol 2015; 80: 1281-1288
    CrossrefPubMedGoogle Scholar
  • 26 Kearns GL, Abdel-Rahman SM, Alander SW. et al. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-1167
    CrossrefPubMedGoogle Scholar
  • 27 Ricci BM. Bridging studies in support of oral pediatric formulation development. Int J Pharm 2013; 457: 323-326
    CrossrefPubMedGoogle Scholar
  • 28 Fernandez E, Perez R, Hernandez A. et al. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics 2011; 3: 53-72
    CrossrefPubMedGoogle Scholar
  • 29 Barrett JS, Della Casa Alberighi O, Läer S. et al. Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther 2012; 92: 40-49
    CrossrefPubMedGoogle Scholar
  • 30 Karalliedde LD, Clarke S, Collignon UG. et al. Adverse Drug Interactions: A Handbook for Prescribers. CRC Press; London, UK: 2016
    Google Scholar
  • 31 Batchelor H, Kendall R, Desset-Brethes S. et al. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients. Eur J Pharm Biopharm 2013; 85: 833-842
    CrossrefPubMedGoogle Scholar
  • 32 Batchelor H, Fotaki N, Klein S. Paediatric oral biopharmaceutics: Key considerations and current challenges. Adv Drug Deliv Rev 2014; 73: 102-126
    CrossrefPubMedGoogle Scholar
  • 33 Kaye JL. Review of paediatric gastrointestinal physiology data relevant to oral drug delivery. Int J Clin Pharm 2011; 33: 20-24
    CrossrefPubMedGoogle Scholar
  • 34 Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 2002; 300: 355-360
    CrossrefPubMedGoogle Scholar
  • 35 McCarver DG, Hines RN. The ontogeny of human drug metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 2002; 300: 361-366
    CrossrefPubMedGoogle Scholar
  • 36 Arant BS. Postnatal development of renal function during the first year of life. Pediatr Nephrol 1987; 1: 308-313
    CrossrefPubMedGoogle Scholar
  • 37 Rhodin MM, Anderson BJ, Peters AM. et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 2009; 24: 67-76
    CrossrefPubMedGoogle Scholar
  • 38 Amidon G, Lennernas H, Shah V. et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420
    CrossrefPubMedGoogle Scholar
  • 39 European Medicines Agency. Guideline on the investigation of bioequivalence. 2010
    PubMed
  • 40 Food and Drug Administration. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry (draft): Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. 2015
    PubMed
  • 41 Abdel-Rahman SM, Amidon GL, Kaul A. et al. Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for children act paediatric formulation initiatives workshop-paediatric biopharmaceutics classification system working group. Clin Ther 2012; 34: S11-S24
    CrossrefPubMedGoogle Scholar
  • 42 Bowles A, Keane J, Ernest T. et al. Specific aspects of gastro-intestinal transit in children for drug delivery design. Int J Pharm 2010; 395: 37-43
    CrossrefPubMedGoogle Scholar
  • 43 Gandhi SV, Rodriguez W, Khan M. et al. Considerations for a Paediatric Biopharmaceutics Classification System (BCS): Application to five drugs. AAPS PharmSciTech 2014; 15: 601-611
    CrossrefPubMedGoogle Scholar
  • 44 Shawahna R. Pediatric Biopharmaceutical Classification System: Using age-appropriate initial gastric volume. AAPS J 2016; 18: 728-736
    CrossrefPubMedGoogle Scholar
  • 45 Sediq A, Kubbinga M, Langguth P. et al. The impact of the EMA change in definition of “dose” on the BCS dose-solubility ratio: A review of the biowaiver monographs. J Pharm Sci 2014; 103: 65-70
    CrossrefPubMedGoogle Scholar
  • 46 Daousani C, Macheras P. Scientific considerations concerning the EMA change in the definition of "dose" of the BCS-based biowaiver guideline and implications for bioequivalence. Int J Pharm 2015; 478: 606-609
    CrossrefPubMedGoogle Scholar
  • 47 Maharaj AR, Edginton AN, Fotaki N. Assessment of age-related changes in paediatric gastrointestinal solubility. Pharm Res 2016; 33: 52-71
    CrossrefPubMedGoogle Scholar
  • 48 Preis M. Orally disintegrating films and mini-tablets – Innovative dosage forms of choice for pediatric use. AAPS PharmSciTech. 2015; 16: 234-241
    CrossrefPubMedGoogle Scholar
  • 49 Ghaleb MA, Barber N, Franklin BD. et al. Systematic review of medication errors in pediatric patients. Ann Pharmacother 2006; 40: 1766-1776
    CrossrefPubMedGoogle Scholar
  • 50 Yin HS, Dreyer BP, Ugboaja DC. et al. Unit of measurement used and parent medication dosing errors. Pediatrics 2014; 134: e354-e361
    CrossrefPubMedGoogle Scholar
  • 51 Fabiano V, Mameli C, Zuccotti GV. Paediatric pharmacology: Remember the excipients. Pharmacol Res 2011; 63: 362-365
    CrossrefPubMedGoogle Scholar
  • 52 Strickley RG, Iwata Q, Will S. et al. Pediatric drugs-a review of commercially available oral formulations. J Pharm Sci 2008; 97: 1731-1774
    CrossrefPubMedGoogle Scholar
  • 53 European Paediatric Formulation Initiative (EuPFI). Safety and Toxicity of Excipients for Paediatrics (STEP) database.
    PubMed
  • 54 Salunke S, Giacoia GP, Tuleu C. The STEP (safety and toxicity of excipients for paediatrics) database. Part 1-A need assessment study. Int J Pharm 2012; 435: 101-111
    CrossrefPubMedGoogle Scholar
  • 55 Salunke S, Brandys B, Giacoia GP. et al. The STEP (Safety and Toxicity of Excipients for Paediatrics) database: Part 2 – the pilot version. Int J Pharm 2013; 457: 310-322
    CrossrefPubMedGoogle Scholar
  • 56 Salunke S, Tuleu C. The STEP database through the end-users eyes – usability study. Int J Pharm 2015; 492: 316-331
    CrossrefPubMedGoogle Scholar
  • 57 Matsui D. Current issues in pediatric medication adherence. Pediatr Drugs 2007; 9: 283-288
    CrossrefPubMedGoogle Scholar
  • 58 Van Riet-Nales DA, De Neef BJ, Schobben A. et al. Acceptability of different oral formulations in infants and preschool children. Arch Dis Child 2013; 98: 725-731
    CrossrefPubMedGoogle Scholar
  • 59 Ranmal S, Tuleu C. Demonstrating evidence of acceptability: The "catch-22" of pediatric formulation development. Clin Pharmacol Ther 2013; 94: 582-584
    CrossrefPubMedGoogle Scholar
  • 60 Mennella JA, Roberts KM, Mathew PS. et al. Children's perceptions about medicines: Individual differences and taste. BMC Pediatr 2015; 15: 130
    CrossrefPubMedGoogle Scholar
  • 61 Jijo A, Flowerlet M. Taste masking of paediatric formulation: A review on technologies, recent trends and regulatory aspects. Int J Pharm Pharmaceut Sci 2014; 6: 12-19
    PubMedGoogle Scholar
  • 62 Arima H, Higashi T, Motoyama K. Improvement of the bitter taste of drugs by complexation with cyclodextrins: Applications, evaluations and mechanisms. Ther Deliv 2012; 3: 633-644
    CrossrefPubMedGoogle Scholar
  • 63 Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral pharmaceuticals: Recent developments and approaches. Drug Dev Ind Pharm 2004; 30: 429-448
    CrossrefPubMedGoogle Scholar
  • 64 Walsh J, Cram A, Woertz K. et al. Playing hide and seek with poorly tasting paediatric medicines: Do not forget the excipients. Adv Drug Del Rev 2014; 73: 14-33
    CrossrefPubMedGoogle Scholar
  • 65 Zajicek A, Fossler MJ, Barrett JS. et al. A report from the pediatric formulations task force: Perspectives on the state of child-friendly oral dosage forms. AAPS J 2013; 15: 1072-1081
    CrossrefPubMedGoogle Scholar
  • 66 Kozarewicz P. Regulatory perspectives on acceptability testing of dosage forms in children. Int J Pharm 2014; 469: 245-248
    CrossrefPubMedGoogle Scholar
  • 67 Lorenz JK, Reo JP, Hendl O. et al. Evaluation of a taste sensor instrument (electronic tongue) for use in formulation development. Int J Pharm 2009; 367: 65-72
    CrossrefPubMedGoogle Scholar
  • 68 Woertz K, Tissen C, Kleinebudde P. et al. Taste sensing systems (electronic tongues) for pharmaceutical applications. Int J Pharm 2011; 417: 256-271
    CrossrefPubMedGoogle Scholar
  • 69 Tuleu C, Breitkreutz J. Educational paper: Formulation-related issues in pediatric clinical pharmacology. Eur J Pediatr 2013; 172: 717-720
    CrossrefPubMedGoogle Scholar
  • 70 Zisowsky J, Krause A, Dingemanse J. Drug Development for Pediatric Populations: Regulatory Aspects. Pharmaceutics 2010; 2: 364-388
    CrossrefPubMedGoogle Scholar
  • 71 Food and Drug Administration. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: The content and format for pediatric use supplements. 1996
    PubMed
  • 72 Food and Drug Administration. Department of health and human services, regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in paediatric Patients; Final Rule. 1998
    PubMed
  • 73 Food and Drug Administration. Best Pharmaceuticals for Children Act. 2002
    PubMed
  • 74 Food and Drug Administration. Paediatric Research Equity Act of. 2003
    PubMed
  • 75 Food and Drug Administration. Amendments Act of. 2007
    PubMed
  • 76 Food and Drug Administration. Guidance for industry. Pediatric study plans: Content of and process for submitting initial pediatric study plans and amended pediatric study plans. 2016
    PubMed
  • 77 Dunne J. The European Regulation on medicines for paediatric use. Paediatr Respir Rev 2007; 8: 177-183
    CrossrefPubMedGoogle Scholar
  • 78 European Commission. Regulation EC No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004.
    PubMed
  • 79 European Medicines Agency. Paediatric Medicines: Overview.
    PubMed
  • 80 European Medicines Agency. European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA).
    PubMed
  • 81 European Commission. Better Medicines for Children: From Concept to Reality. Progress report on the Paediatric regulation No 1901/2006. 2013
    PubMed
  • 82 European Medicines Agency. 10-year Report to the European Commission. EMA/231225/2015. 2016
    PubMed
  • 83 van Riet-Nales DA, Römkens EG, Saint-Raymond A. et al. Oral medicines for children in the European paediatric investigation plans. PLoS One 2014; 9: e98348
    CrossrefPubMedGoogle Scholar
  • 84 Wimmer S, Rascher W, McCarthy S. et al. The EU paediatric regulation: still a large discrepancy between therapeutic needs and approved paediatric investigation plans. Paediatr Drugs 2014; 16: 397-406
    CrossrefPubMedGoogle Scholar
  • 85 World Health Organization. Report of the informal expert meeting on dosage forms of medicines for children. 2008
    PubMed
  • 86 World Health Organization. WHO Model Formulary for Children. 2010
    PubMed
  • 87 World Health Organization. WHO model list of essential medicines for children, 4th list. 2013
    PubMed
  • 88 Dunne J, Rodriguez WJ, Dianne Murphy M. et al. Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs. Pediatrics 2011; 128: e1242-e1249
    CrossrefPubMedGoogle Scholar
  • 89 European Medicines Agency. Concept paper on extrapolation of efficacy and safety in medicine development. 2013
    PubMed
  • 90 European Medicines Agency. Reflection paper on extrapolation of efficacy and safety in paediatric medicine development (draft). 2016
    PubMed
  • 91 Manolis E, Osman TE, Herold R. et al. Role of modeling and simulation in paediatric investigation plans. Paediatric Anesthesia 2011; 21: 214-221
    CrossrefPubMedGoogle Scholar
  • 92 Food and Drug Administration. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Exposure-Response Relationships — Study Design, Data Analysis, and Regulatory Applications. 2003
    PubMed
  • 93 Cella M, Gorter de Vries F, Burger D. et al. A model-based approach to dose selection in early pediatric development. Clin Pharmacol Ther 2010; 87: 294-302
    CrossrefPubMedGoogle Scholar
  • 94 Vinks AA, Emoto C, Fukuda T. Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children. Clin Pharmacol Ther 2015; 98: 298-308
    CrossrefPubMedGoogle Scholar
  • 95 Villiger A, Stillhart C, Parrott N. et al. Using Physiologically Based Pharmacokinetic (PBPK) modelling to gain Insights into the effect of physiological factors on oral absorption in paediatric populations. AAPS J 2016; 18: 933-947
    CrossrefPubMedGoogle Scholar